Situation: A nurse works in a private fertility center that offers assisted reproductive technology (ART) and counsels couples about their options. A 30-year-old woman with irregular ovulation is started on clomiphene citrate. Which statement shows that she understood the nurse's teaching?

Clomiphene citrate is a selective estrogen receptor modulator used to induce ovulation. Visual disturbances such as blurring or flashes of light require stopping the drug and reporting. Hot flashes, bloating, and mood changes are common expected side effects, and the drug raises the chance of multiple pregnancy, mostly twins.

Understanding clomiphene citrate teaching

Clomiphene citrate is a selective estrogen receptor modulator (SERM) that blocks estrogen feedback at the hypothalamus, leading to increased gonadotropin-releasing hormone (GnRH) pulses and subsequent ovulation induction. For a 30-year-old woman with irregular ovulation, the key teaching points center on recognizing which effects are expected and which require immediate discontinuation.

Visual disturbances such as blurred vision, flashes of light, or scotomata are a serious adverse effect that mandates stopping clomiphene and notifying the provider immediately. This is the priority teaching point because visual symptoms may indicate drug toxicity affecting the optic pathway, and continued use can lead to prolonged or irreversible visual changes. The correct response reflects this understanding.

Hot flashes, bloating, breast tenderness, and mood swings are common, expected side effects of clomiphene due to its anti-estrogenic action on peripheral tissues. They do not indicate drug failure or allergy. Key point! Expected side effects are not reasons to stop the medication; only visual changes, severe abdominal pain suggesting ovarian hyperstimulation, or signs of an allergic reaction warrant discontinuation.

Regarding multiple pregnancy, clomiphene increases the likelihood of multiple ovulation and therefore raises the chance of twins. The rate of twin gestation with clomiphene is approximately 5–10%, compared with a baseline twin rate of about 1–2% in spontaneous conceptions. This is a counseling point that must be addressed before starting therapy.

The study by Blenner ^[1] documented that mood swings occurred in 9 of 14 women using clomiphene, confirming that mood changes are a common and expected drug effect rather than an allergic reaction. The research described a three-phase response: initially lacking awareness that mood swings were drug-related, then gaining awareness of the connection, and finally developing strategies to manage the emotional lability. This supports the teaching that mood swings do not require stopping the medication; instead, patients benefit from anticipatory guidance and coping strategies.

Effect	Expected or concerning	Nursing action
Blurred vision or visual flashes	Concerning; possible drug toxicity	Stop clomiphene; report to provider immediately
Hot flashes	Expected; anti-estrogenic effect	Continue drug; provide comfort measures
Mood swings	Expected; documented in 9/14 women [1]	Continue drug; offer support and coping strategies
Bloating or pelvic discomfort	Expected; ovarian enlargement	Continue drug; monitor for severe pain or ascites
Multiple pregnancy risk	Increased; mostly twins	Counsel before starting; monitor follicular response

Watch out! Visual symptoms are the only option listed that requires stopping clomiphene. Hot flashes and mood swings are expected side effects, not indicators of treatment failure or allergy. A patient who stops the drug for these reasons would unnecessarily interrupt ovulation induction.

The nurse should teach that clomiphene raises the chance of multiple pregnancy, primarily twins, and that this risk is inherent to ovulation induction. This distinguishes clomiphene from natural conception and is essential for informed consent before initiating therapy.